KALV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kalvista Pharmaceuticals Inc (KALV) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the stock shows some potential for growth in the next month and analysts maintain positive ratings, the lack of significant positive catalysts, weak financial performance, and hedge fund selling trends suggest a cautious approach. The investor should wait for clearer signs of sustained growth or stronger entry signals.
The stock's MACD is negative and expanding, indicating a bearish momentum. RSI is neutral at 40.24, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Current price is near the support level (S1: 18.953), but no strong upward momentum is evident.
Analyst ratings remain positive with price targets ranging from $28 to $42, reflecting optimism about the company's growth prospects. The launch of Ekterly has shown strong initial performance, with sustainable revenue growth from refills.
Hedge funds are selling heavily, with a 7382.63% increase in selling activity over the last quarter. Financial performance in Q4 2025 was weak, with a significant drop in net income (-210.62% YoY) and EPS (-186.41% YoY). No significant insider or congress trading trends have been observed.
In Q4 2025, revenue remained flat YoY at $35.39M. However, net income dropped significantly to -$49.39M, and EPS declined to 0.89, reflecting poor profitability. Gross margin remained strong at 94.77%, but the lack of revenue growth and declining profitability are concerning.
Analysts maintain positive ratings with price targets ranging from $28 to $42. Recent updates highlight strong growth in Ekterly sales, particularly from refills, which suggests sustainable demand. However, the stock's current price of $19.08 is significantly below the lowest price target, indicating potential upside but also risks.
